# Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.

> **NCT07742956** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Allink Biotherapeutics Co., Ltd.** · enrollment: 156 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** ALK201 for injection
- **DRUG:** Ivonescimab Injection

## Key facts

- **NCT ID:** NCT07742956
- **Lead sponsor:** Shanghai Allink Biotherapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-20
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07742956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07742956, "Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07742956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*